<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="47042">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02082327</url>
  </required_header>
  <id_info>
    <org_study_id>AT1001-018</org_study_id>
    <secondary_id>2013-005553-75</secondary_id>
    <nct_id>NCT02082327</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study To Evaluate the Safety of Migalastat Hydrochloride Given Intravenously to Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Dose Escalation Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of Migalastat Hydrochloride Given Intravenously to Healthy Volunteers With an Open-Label, Randomized, Two-Way Crossover Arm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amicus Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amicus Therapeutics</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of
      IV migalastat HCl alone and to determine absolute bioavailability for oral migalastat HCl as
      compared to IV administered migalastat HCl in healthy volunteers. The data from this study
      will help us understand how migalastat works in the body and will help us determine what
      would be an effective dose in future studies with migalastat hydrochloride.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Plasma pharmacokinetics of migalastat</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2.0, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48</time_frame>
    <safety_issue>No</safety_issue>
    <description>To investigate the effect on the body of migalastat following a single 2 hour IV  infusion in healthy subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of migalastat</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events, clinical laboratory test values, vital signs, ECG, physical examinations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics of migalastat</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2.0, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess the dose proportionality of migalastat following a single 2 hour IV infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary pharmacokinetics</measure>
    <time_frame>Pre dose, between 0-6, 6-12 and 12-24 hours after start of infusion</time_frame>
    <safety_issue>No</safety_issue>
    <description>To estimate the urinary excretion of unchanged migalastat following a single 2 hour IV infusion in healthy subjects</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">31</enrollment>
  <condition>Fabry Disease</condition>
  <arm_group>
    <arm_group_label>0.3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV infusion of migalastat HCl or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV infusion of migalastat HCl or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV infusion of migalastat HCl or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>150 mg IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg single IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>150 mg oral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg single oral dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV migalastat HCl</intervention_name>
    <arm_group_label>0.3 mg/kg</arm_group_label>
    <arm_group_label>1 mg/kg</arm_group_label>
    <arm_group_label>10 mg/kg</arm_group_label>
    <arm_group_label>150 mg IV</arm_group_label>
    <arm_group_label>150 mg oral</arm_group_label>
    <other_name>AT1001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV placebo</intervention_name>
    <arm_group_label>0.3 mg/kg</arm_group_label>
    <arm_group_label>1 mg/kg</arm_group_label>
    <arm_group_label>10 mg/kg</arm_group_label>
    <other_name>Sodium Chloride 0.9%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral migalastat HCl</intervention_name>
    <arm_group_label>150 mg IV</arm_group_label>
    <arm_group_label>150 mg oral</arm_group_label>
    <other_name>AT1001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females between 18 and 45 years of age.

          -  Body weight range ≥ 50 kg ≤ 100 kg and BMI within the range 18.5 - 29.9 kg/m2.

          -  Healthy as determined by a responsible and experienced physician, based on a medial
             evaluation.

          -  Male and female subjects of childbearing potential agree to adhere to the
             contraception requirements.

          -  Capable of giving written informed consent.

        Exclusion Criteria:

          -  History of sensitivity to migalastat HCl or related iminosugars (eg, miglitol,
             miglustat), or other significant drug allergy.

          -  Past medical history, or physical examination findings, of clinically significant
             abnormalities that may put the subject at risk or interfere with outcome variables.

          -  Positive pre-study drug/alcohol screen.

          -  Pregnant or lactating females.

          -  The subject has participated in a clinical trial and has received an investigational
             product within 60 days prior to the first dosing day in the current study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor Clinical Research</last_name>
    <role>Study Director</role>
    <affiliation>Amicus Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA International</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Schuilenga-Hut, PhD</last_name>
      <phone>31504022693</phone>
      <email>SchuilengaPetra@PRAIntl.com</email>
    </contact>
    <investigator>
      <last_name>Nada Al Kotbi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 30, 2014</lastchanged_date>
  <firstreceived_date>March 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fabry Disease</keyword>
  <keyword>Fabry</keyword>
  <keyword>Lysosomal storage disorders</keyword>
  <keyword>LSD</keyword>
  <keyword>Amicus</keyword>
  <keyword>migalastat HCl</keyword>
  <keyword>migalastat</keyword>
  <keyword>AT1001</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
